Beta-1,3/1,6-D-glucan (yeast or oat)

Beta-1,3/1,6-D-glucan is a polysaccharide from yeast cell walls or from oats, sold as an immune supplement and marketed for cancer prevention. There is no solid evidence for this use: the available data do not show that taking this supplement lowers cancer risk. What actually reduces that risk are other measures – not smoking, limiting alcohol, keeping a healthy weight, HPV and hepatitis B vaccination, and age-appropriate screening. This supplement should not replace approaches with proven benefit, or you may miss the care or testing you actually need.

Beta-1,3/1,6-D-glucan is a polysaccharide from the cell wall of baker's yeast or from oats. Supplements market it for chronic fatigue and immune support. For chronic fatigue, beta-glucan has not shown convincing benefit, and there is no good clinical evidence for this use. Persistent fatigue calls for finding the cause (anemia, hypothyroidism, iron or B12 deficiency, sleep problems, depression) and treating that. Beta-glucan is harmless here, but it should not replace treatment your doctor has chosen, since that can mean missing a condition that does respond to therapy.

Yeast beta-glucan is sold as a «natural cold remedy» promising symptom duration and severity reduction. Talbott 2009 and Auinger 2013 RCTs showed moderate cold symptom reduction with Wellmune 250 mg/day, but the effect did not exceed clinically significant threshold and depended on population (marathoners, healthy volunteers, not patients with active cold). EFSA 2013 and 2014 rejected the health claim. No Cochrane systematic review on beta-glucan in the common cold. AAFP 2019 and SEIMC 2020 for the common cold list symptomatic therapy first-line (paracetamol, nasal irrigation, rest, fluids); beta-glucan is not mentioned. If beta-glucan was recommended as a substitute for symptomatic therapy or antibiotic in bacterial superinfection, consider seeking a second opinion.

Yeast beta-glucan (Wellmune, Saccharomyces cerevisiae) is widely sold as a «natural immunomodulator» promising URI frequency reduction and cold symptom relief. Small RCTs Talbott 2009 in 75 post-marathon athletes and Auinger 2013 in 100 healthy volunteers showed moderate URI frequency and severity reduction with Wellmune 250 mg/day × 12 weeks. Evidence quality is limited by small samples, single-centre design and potential conflict of interest (sponsored by manufacturer). EFSA 2013 reviewed the «yeast beta-glucan helps to maintain body's defence against pathogens» claim and rejected it due to insufficient data. EFSA 2014 rejected again. AAFP 2019 and SEIMC 2020 for the common cold list symptomatic therapy first-line; beta-glucan is not in international guidelines. Oat beta-glucan as dietary fibre is not related to immune claims.